Smith & Nephew Snats stock kpis
Want to see SNN full AI Analyst Report?
Revenue by Segment
In Q2 2026, Smith & Nephew Snats reported revenue by segment of $614.00M (Orthopaedics), $527.00M (Sports Medicine & ENT) and $456.00M (Advanced Wound Management).
Analyzes revenue contributions from different business units, indicating which segments are leading growth and how diversified the company's income streams are.
All three segments hit multi-year revenue highs in late‑2025, driven by new product launches and CORI-related orthopaedic momentum, signaling broad-based recovery from the pandemic trough. Orthopaedics is strengthening but remains lumpy as U.S. knee rollouts and the Integrity acquisition are phased (marginally dilutive in 2026). Advanced Wound Management has lagged and faces CMS reimbursement pressure that could offset growth despite planned cost savings. Management’s 2026 guidance implies stronger H2 revenue and profit, but tariffs, China VBP and wound pricing are key near‑term risks to monitor.
SNN Revenue by Segment
| Period | Orthopaedics | Sports Medicine & ENT | Advanced Wound Management |
|---|---|---|---|
| Q2 2026Jun 30, 2026 | $614.00M | $527.00M | $456.00M |
| Q1 2026Mar 31, 2026 | $599.00M | $491.00M | $411.00M |
| Q4 2025Dec 31, 2025 | $667.00M | $541.00M | $494.00M |
| Q3 2025Sep 28, 2025 | $577.00M | $469.00M | $455.00M |
| Q2 2025Jun 29, 2025 | $615.00M | $479.00M | $459.00M |
| Q1 2025Mar 30, 2025 | $578.00M | $444.00M | $385.00M |
| Q4 2024Dec 31, 2024 | $608.00M | $494.00M | $469.00M |
| Q3 2024Sep 28, 2024 | $549.00M | $441.00M | $422.00M |
| Q2 2024Jun 29, 2024 | $581.00M | $448.00M | $412.00M |
| Q1 2024Mar 30, 2024 | $567.00M | $441.00M | $378.00M |
| Q4 2023Dec 31, 2023 | $576.00M | $462.00M | $420.00M |
| Q3 2023Sep 30, 2023 | $536.00M | $425.00M | $396.00M |
| Q2 2023Jul 01, 2023 | $554.00M | $422.00M | $403.00M |
| Q1 2023Apr 01, 2023 | $548.00M | $422.00M | $386.00M |
| Q4 2022Dec 31, 2022 | $549.00M | $430.00M | $386.00M |
| Q3 2022Oct 01, 2022 | $492.00M | $382.00M | $376.00M |
| Q2 2022Jul 02, 2022 | $530.00M | $381.00M | $382.00M |
| Q1 2022Apr 02, 2022 | $541.00M | $396.00M | $369.00M |
| Q4 2021Dec 31, 2021 | $552.00M | $416.00M | $378.00M |
| Q3 2021Oct 02, 2021 | $508.00M | $379.00M | $379.00M |
| Q2 2021Jul 03, 2021 | $557.00M | $391.00M | $387.00M |
| Q1 2021Apr 03, 2021 | $540.00M | $373.00M | $351.00M |
| Q4 2020Dec 31, 2020 | $545.00M | $408.00M | $373.00M |
| Q3 2020Sep 26, 2020 | $512.00M | $350.00M | $338.00M |
| Q2 2020Jun 27, 2020 | $364.00M | $247.00M | $290.00M |
| Q1 2020Mar 28, 2020 | $497.00M | $328.00M | $309.00M |

